Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Headache HELP
Based on 8,033 articles published since 2008
||||

These are the 8033 published articles about Headache that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. 2019

Sacco, Simona / Bendtsen, Lars / Ashina, Messoud / Reuter, Uwe / Terwindt, Gisela / Mitsikostas, Dimos-Dimitrios / Martelletti, Paolo. ·Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, via Vetoio, 67100, L'Aquila, Italy. simona.sacco@univaq.it. · Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. · Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany. · Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. · 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece. · Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy. ·J Headache Pain · Pubmed #30651064.

ABSTRACT: BACKGROUND AND AIM: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention. METHODS: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. RESULTS: We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab, fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts' opinion. CONCLUSION: Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical practice.

2 Guideline European headache federation guideline on idiopathic intracranial hypertension. 2018

Hoffmann, Jan / Mollan, Susan P / Paemeleire, Koen / Lampl, Christian / Jensen, Rigmor H / Sinclair, Alexandra J. ·Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Wellcome Foundation Building, Denmark Hill Campus, King's College London, London, SE5 9PJ, UK. jan.hoffmann@kcl.ac.uk. · Birmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK. · Department of Neurology, Ghent University Hospital, Ghent, Belgium. · Headache Medical Centre, Seilerstaette Linz, Ordensklinikum Linz, Barmherzige Schwestern, Linz, Austria. · Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Glostrup, Denmark. · Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, UK. ·J Headache Pain · Pubmed #30298346.

ABSTRACT: BACKGROUND: Idiopathic Intracranial Hypertension (IIH) is characterized by an elevation of intracranial pressure (ICP no identifiable cause. The aetiology remains largely unknown, however observations made in a number of recent clinical studies are increasing the understanding of the disease and now provide the basis for evidence-based treatment strategies. METHODS: The Embase, CDSR, CENTRAL, DARE and MEDLINE databases were searched up to 1st June 2018. We analyzed randomized controlled trials and systematic reviews that investigate IIH. RESULTS: Diagnostic uncertainty, headache morbidity and visual loss are among the highest concerns of clinicians and patients in this disease area. Research in this field is infrequent due to the rarity of the disease and the lack of understanding of the underlying pathology. CONCLUSIONS: This European Headache Federation consensus paper provides evidence-based recommendations and practical advice on the investigation and management of IIH.

3 Guideline ACR Appropriateness Criteria 2018

Anonymous1341079 / Hayes, Laura L / Palasis, Susan / Bartel, Twyla B / Booth, Timothy N / Iyer, Ramesh S / Jones, Jeremy Y / Kadom, Nadja / Milla, Sarah S / Myseros, John S / Pakalnis, Ann / Partap, Sonia / Robertson, Richard L / Ryan, Maura E / Saigal, Gaurav / Soares, Bruno P / Tekes, Aylin / Karmazyn, Boaz K. ·Principal Author, Children's Healthcare of Atlanta, Atlanta, Georgia. Electronic address: lauralhayes@gmail.com. · Panel Chair, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia. · Global Advanced Imaging, PLLC, Little Rock, Arizona. · Children's Medical Center, Dallas, Texas. · Seattle Children's Hospital, Seattle, Washington. · Texas Children's Hospital, Houston, Texas. · Emory University and Children's of Atlanta (Egleston), Atlanta, Georgia. · Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia. · Children's National Medical Center, Washington, District of Columbia; neurosurgical consultant. · Nationwide Children's Hospital, Columbus, Ohio; American Academy of Neurology. · Stanford University, Stanford, California; American Academy of Pediatrics. · Boston Children's Hospital, Boston, Massachusetts. · Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. · Jackson Memorial Hospital, Miami, Florida. · Johns Hopkins University School of Medicine, Baltimore, Maryland. · Specialty Chair, Riley Hospital for Children Indiana University, Indianapolis, Indiana. ·J Am Coll Radiol · Pubmed #29724429.

ABSTRACT: Headaches in children are not uncommon and have various causes. Proper neuroimaging of these children is very specific to the headache type. Care must be taken to choose and perform the most appropriate initial imaging examination in order to maximize the ability to properly determine the cause with minimum risk to the child. This evidence-based report discusses the different headache types in children and provides appropriate guidelines for imaging these children. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

4 Guideline European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. 2017

Pace, Andrea / Dirven, Linda / Koekkoek, Johan A F / Golla, Heidrun / Fleming, Jane / Rudà, Roberta / Marosi, Christine / Le Rhun, Emilie / Grant, Robin / Oliver, Kathy / Oberg, Ingela / Bulbeck, Helen J / Rooney, Alasdair G / Henriksson, Roger / Pasman, H Roeline W / Oberndorfer, Stefan / Weller, Michael / Taphoorn, Martin J B / Anonymous3531104. ·Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy. · Department of Neurology, Leiden University Medical Center, Leiden, Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands. · Department of Palliative Medicine, University Hospital of Cologne, Cologne, Germany. · Department of Palliative Medicine, University Hospital Waterford, Waterford, Ireland. · Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy. · Department of Internal Medicine I, Clinical Division of Medical Oncology, Medical University of Vienna, Vienna, Austria. · Neuro-Oncology Unit, Department of Neurosurgery, University Hospital, Lille, France; Breast Unit, Department of Medical Oncology, Oscar Lambret Center, Lille, France. · Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, UK. · International Brain Tumour Alliance, Tadworth, UK. · Department of Neuroscience, Cambridge University Hospitals, Cambridge, UK. · brainstrust, Cowes, Isle of Wight, UK. · Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. · Regional Cancer Center Stockholm Gotland, Stockholm, Sweden; Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden. · Amsterdam Public Health Research Institute, Department of Public and Occupational Health, VU University Medical Center, Amsterdam, Netherlands. · Department of Neurology, University Clinic St Pölten, Karl Landsteiner Private University and Karl Landsteiner Institute for Neurology and Neuropsychology, St Pölten, Austria. · Department of Neurology, University Hospital, University of Zurich, Zurich, Switzerland. · Department of Neurology, Leiden University Medical Center, Leiden, Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands. Electronic address: m.taphoorn@haaglandenmc.nl. ·Lancet Oncol · Pubmed #28593859.

ABSTRACT: Patients with glioma present with complex palliative care needs throughout their disease trajectory. The life-limiting nature of gliomas and the presence of specific symptoms related to neurological deterioration necessitate an appropriate and early palliative care approach. The multidisciplinary palliative care task force of the European Association of Neuro-Oncology did a systematic review of the available scientific literature to formulate the best possible evidence-based recommendations for the palliative care of adult patients with glioma, with the aim to reduce symptom burden and improve the quality of life of patients and their caregivers, particularly in the end-of-life phase. When recommendations could not be made because of the scarcity of evidence, the task force either used evidence from studies of patients with systemic cancer or formulated expert opinion. Areas of palliative care that currently lack evidence and thus deserve attention for further research are fatigue, disorders of behaviour and mood, interventions for the needs of caregivers, and timing of advance care planning.

5 Guideline AAN Updates Guidelines on the Uses of Botulinum Neurotoxin. 2017

Wilkes, Jennifer. · ·Am Fam Physician · Pubmed #28145664.

ABSTRACT: -- No abstract --

6 Guideline French Guidelines For the Emergency Management of Headaches. 2016

Moisset, X / Mawet, J / Guegan-Massardier, E / Bozzolo, E / Gilard, V / Tollard, E / Feraud, T / Noëlle, B / Rondet, C / Donnet, A. ·Inserm U-1107, NeuroDol, Clermont Université, Université d'Auvergne, 49, boulevard François-Mitterrand, 63000 Clermont-Ferrand, France; CHU Gabriel Montpied, Service de Neurologie, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France. Electronic address: xavier.moisset@gmail.com. · Centre d'urgences céphalées, département de Neurologie, GH Saint-Louis-Lariboisière, Assistance Publique des Hôpitaux de Paris AP-HP, Université Paris Denis Diderot et DHU NeuroVasc Sorbonne Paris-Cité, Paris, France. · Service de neurologie, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France. · Service de neurologie, Pôle des Neurosciences Cliniques, CHU de Nice, Nice, France. · Service de neurochirurgie, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France. · Service de neuroradiologie, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France. · Service d'accueil des urgences, hôpital Timone, boulevard Jean-Moulin, 264, rue Saint-Pierre, 13385 Marseille, France. · Cabinet privé, 35, allée de Champrond, 38330 Saint-Ismier, France. · Faculté de médecine, Service de médecine générale, Université Pierre-et-Marie-Curie Paris 06, Paris, France. · Inserm U-1107, NeuroDol, Clermont Université, Université d'Auvergne, 49, boulevard François-Mitterrand, 63000 Clermont-Ferrand, France; Centre d'évaluation et de traitement de la douleur, hôpital Timone, boulevard Jean-Moulin, 264, rue Saint-Pierre, 13385 Marseille, France. ·Rev Neurol (Paris) · Pubmed #27377828.

ABSTRACT: -- No abstract --

7 Guideline Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. 2016

Simpson, David M / Hallett, Mark / Ashman, Eric J / Comella, Cynthia L / Green, Mark W / Gronseth, Gary S / Armstrong, Melissa J / Gloss, David / Potrebic, Sonja / Jankovic, Joseph / Karp, Barbara P / Naumann, Markus / So, Yuen T / Yablon, Stuart A. ·From the Department of Neurology (D.M.S., M.W.G.), Icahn School of Medicine at Mount Sinai, New York, NY · Human Motor Control Section (M.H.), National Institute of Neurological Disorders and Stroke (B.P.K.), National Institutes of Health, Bethesda, MD · Department of Neurology (E.J.A.), Bronson Neuroscience Center, Bronson Methodist Hospital, Kalamazoo, MI · Department of Neurological Sciences (C.L.C.), Rush University Medical Center, Chicago, IL · Department of Neurology (G.S.G.), University of Kansas School of Medicine, Kansas City · Department of Neurology (M.J.A.), University of Maryland, Baltimore · Department of Neurology (D.G.), Geisinger Health System, Danville, PA · Department of Neurology (S.P.), Kaiser Permanente Los Angeles Medical Center, CA · Parkinson's Disease Center and Movement Disorders Clinic (J.J.), Department of Neurology, Baylor College of Medicine, Houston, TX · Department of Neurology and Clinical Neurophysiology (M.N.), Klinikum Augsburg, Germany · Department of Neurology and Neurological Sciences (Y.T.S.), Stanford University, Palo Alto, CA · and Division of Physical Medicine and Rehabilitation (S.A.Y.), University of Alberta, Edmonton, Canada. ·Neurology · Pubmed #27164716.

ABSTRACT: OBJECTIVE: To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity. METHODS: We searched the literature for relevant articles and classified them using 2004 AAN criteria. RESULTS AND RECOMMENDATIONS: Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is possibly effective and may be considered (Level C). CD: AboBoNT-A and rimabotulinumtoxinB (rimaBoNT-B) are established as effective and should be offered (Level A), and onaBoNT-A and incoBoNT-A are probably effective and should be considered (Level B). Adult spasticity: AboBoNT-A, incoBoNT-A, and onaBoNT-A are established as effective and should be offered (Level A), and rimaBoNT-B is probably effective and should be considered (Level B), for upper limb spasticity. AboBoNT-A and onaBoNT-A are established as effective and should be offered (Level A) for lower-limb spasticity. Headache: OnaBoNT-A is established as effective and should be offered to increase headache-free days (Level A) and is probably effective and should be considered to improve health-related quality of life (Level B) in chronic migraine. OnaBoNT-A is established as ineffective and should not be offered for episodic migraine (Level A) and is probably ineffective for chronic tension-type headaches (Level B).

8 Guideline American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department. 2015

Perkins, Jack / Ho, Jeffrey D / Vilke, Gary M / DeMers, Gerard. ·Department of Emergency Medicine, University of Minnesota Medical School, Minneapolis, Minnesota; Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota. · Department of Emergency Medicine, Virginia Tech Carilion School of Medicine, Roanoke, Virginia. · Department of Emergency Medicine, University of California at San Diego Medical Center, San Diego, California. · Department of Emergency Medicine, Naval Medical Center San Diego, San Diego, California. ·J Emerg Med · Pubmed #25837231.

ABSTRACT: BACKGROUND: Droperidol (Inapsine®, Glaxosmithkline, Brent, UK) is a butyrophenone used in emergency medicine practice for a variety of uses. QT prolongation is a well-known adverse effect of this class of medications. Of importance to note, QT prolongation is noted with multiple medication classes, and droperidol increases QT interval in a dose-dependent fashion among susceptible individuals. The primary goal of this literature search was to determine the reported safety issues of droperidol in emergency department management of patients. METHODS: A MEDLINE literature search was conducted from January 1995 to January 2014 and limited to human studies written in English for articles with keywords of droperidol/Inapsine. Guideline statements and nonsystematic reviews were excluded. Studies identified then underwent a structured review from which results could be evaluated. RESULTS: There were 542 papers on droperidol screened, and 35 appropriate articles were rigorously reviewed in detail and recommendations given. CONCLUSION: Droperidol is an effective and safe medication in the treatment of nausea, headache, and agitation. The literature search did not support mandating an electrocardiogram or telemetry monitoring for doses < 2.5 mg given either intramuscularly or intravenously. Intramuscular doses of up to 10 mg of droperidol seem to be as safe and as effective as other medications used for sedation of agitated patients.

9 Guideline Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. 2014

Schiffman, Eric / Ohrbach, Richard / Truelove, Edmond / Look, John / Anderson, Gary / Goulet, Jean-Paul / List, Thomas / Svensson, Peter / Gonzalez, Yoly / Lobbezoo, Frank / Michelotti, Ambra / Brooks, Sharon L / Ceusters, Werner / Drangsholt, Mark / Ettlin, Dominik / Gaul, Charly / Goldberg, Louis J / Haythornthwaite, Jennifer A / Hollender, Lars / Jensen, Rigmor / John, Mike T / De Laat, Antoon / de Leeuw, Reny / Maixner, William / van der Meulen, Marylee / Murray, Greg M / Nixdorf, Donald R / Palla, Sandro / Petersson, Arne / Pionchon, Paul / Smith, Barry / Visscher, Corine M / Zakrzewska, Joanna / Dworkin, Samuel F / Anonymous3490783 / Anonymous3500783. · ·J Oral Facial Pain Headache · Pubmed #24482784.

ABSTRACT: AIMS: The original Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) Axis I diagnostic algorithms have been demonstrated to be reliable. However, the Validation Project determined that the RDC/TMD Axis I validity was below the target sensitivity of ≥ 0.70 and specificity of ≥ 0.95. Consequently, these empirical results supported the development of revised RDC/TMD Axis I diagnostic algorithms that were subsequently demonstrated to be valid for the most common pain-related TMD and for one temporomandibular joint (TMJ) intra-articular disorder. The original RDC/TMD Axis II instruments were shown to be both reliable and valid. Working from these findings and revisions, two international consensus workshops were convened, from which recommendations were obtained for the finalization of new Axis I diagnostic algorithms and new Axis II instruments. METHODS: Through a series of workshops and symposia, a panel of clinical and basic science pain experts modified the revised RDC/TMD Axis I algorithms by using comprehensive searches of published TMD diagnostic literature followed by review and consensus via a formal structured process. The panel's recommendations for further revision of the Axis I diagnostic algorithms were assessed for validity by using the Validation Project's data set, and for reliability by using newly collected data from the ongoing TMJ Impact Project-the follow-up study to the Validation Project. New Axis II instruments were identified through a comprehensive search of the literature providing valid instruments that, relative to the RDC/TMD, are shorter in length, are available in the public domain, and currently are being used in medical settings. RESULTS: The newly recommended Diagnostic Criteria for TMD (DC/TMD) Axis I protocol includes both a valid screener for detecting any pain-related TMD as well as valid diagnostic criteria for differentiating the most common pain-related TMD (sensitivity ≥ 0.86, specificity ≥ 0.98) and for one intra-articular disorder (sensitivity of 0.80 and specificity of 0.97). Diagnostic criteria for other common intra-articular disorders lack adequate validity for clinical diagnoses but can be used for screening purposes. Inter-examiner reliability for the clinical assessment associated with the validated DC/TMD criteria for pain-related TMD is excellent (kappa ≥ 0.85). Finally, a comprehensive classification system that includes both the common and less common TMD is also presented. The Axis II protocol retains selected original RDC/TMD screening instruments augmented with new instruments to assess jaw function as well as behavioral and additional psychosocial factors. The Axis II protocol is divided into screening and comprehensive self report instrument sets. The screening instruments' 41 questions assess pain intensity, pain-related disability, psychological distress, jaw functional limitations, and parafunctional behaviors, and a pain drawing is used to assess locations of pain. The comprehensive instruments, composed of 81 questions, assess in further detail jaw functional limitations and psychological distress as well as additional constructs of anxiety and presence of comorbid pain conditions. CONCLUSION: The recommended evidence-based new DC/TMD protocol is appropriate for use in both clinical and research settings. More comprehensive instruments augment short and simple screening instruments for Axis I and Axis II. These validated instruments allow for identification of patients with a range of simple to complex TMD presentations.

10 Guideline Neuromodulation of chronic headaches: position statement from the European Headache Federation. 2013

Martelletti, Paolo / Jensen, Rigmor H / Antal, Andrea / Arcioni, Roberto / Brighina, Filippo / de Tommaso, Marina / Franzini, Angelo / Fontaine, Denys / Heiland, Max / Jürgens, Tim P / Leone, Massimo / Magis, Delphine / Paemeleire, Koen / Palmisani, Stefano / Paulus, Walter / May, Arne / Anonymous510773. · ·J Headache Pain · Pubmed #24144382.

ABSTRACT: The medical treatment of patients with chronic primary headache syndromes (chronic migraine, chronic tension-type headache, chronic cluster headache, hemicrania continua) is challenging as serious side effects frequently complicate the course of medical treatment and some patients may be even medically intractable. When a definitive lack of responsiveness to conservative treatments is ascertained and medication overuse headache is excluded, neuromodulation options can be considered in selected cases. Here, the various invasive and non-invasive approaches, such as hypothalamic deep brain stimulation, occipital nerve stimulation, stimulation of sphenopalatine ganglion, cervical spinal cord stimulation, vagus nerve stimulation, transcranial direct current stimulation, repetitive transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation are extensively published although proper RCT-based evidence is limited. The European Headache Federation herewith provides a consensus statement on the clinical use of neuromodulation in headache, based on theoretical background, clinical data, and side effect of each method. This international consensus further gives recommendations for future studies on these new approaches. In spite of a growing field of stimulation devices in headaches treatment, further controlled studies to validate, strengthen and disseminate the use of neurostimulation are clearly warranted. Consequently, until these data are available any neurostimulation device should only be used in patients with medically intractable syndromes from tertiary headache centers either as part of a valid study or have shown to be effective in such controlled studies with an acceptable side effect profile.

11 Guideline [Rapid headache guidelines. Neurology consensus between Neurology (SAN) and Primary Care (SEMERGEN Andalucía). Referral criteria]. 2012

Gil Campoy, J A / González Oria, C / Fernández Recio, M / Gómez Aranda, F / Jurado Cobo, C M / Heras Pérez, J A / Anonymous3250754 / Anonymous3260754. ·Medicina de Familia, Sociedad Española de Médicos de Atención Primaria, España. jagilcamp@gmail.com ·Semergen · Pubmed #23544726.

ABSTRACT: Headache is one of the most frequent reasons for consultation in our health centers, something which should not be surprising if we consider that is one of the most common symptoms experienced by the population. The main concern of the family physician and emergency physician is to reach a correct diagnosis by clinical history and a basic neurological examination and adapted to the time and means at its disposal. In case of diagnostic doubts or suspected secondary headache, the primary care physician or emergency medical have to refer the patient to be studied and/or treated for Neurology services, such referral shall be made with varying degrees of urgency depending on the presence, or not, of symptoms or signs of alarm. A working group consisting of Neurologists of Sociedad Andaluza de Neurología (SAN) to provide services in different hospitals in Andalucía and Family Physicians representatives of the Sociedad Andaluza de Medicina Familiar y Comunitaria (SAMFyC) and the Sociedad Española de Médicos de Atención Primaria (SEMERGEN Andalucía), has developed a Quick Guide headache, which addresses the more practical aspects for the diagnosis, treatment and monitoring of patients with headache. We show you in this paper, the chapter that deals the alarm criteria and referral.

12 Guideline Report of the Croatian Society for Neurovascular Disorders, Croatian Medical Association. Evidence based guidelines for treatment of primary headaches--2012 update. 2012

Vuković Cvetković, Vlasta / Kes, Vanja Basić / Serić, Vesna / Solter, Vesna Vargek / Demarin, Vida / Janculjak, Davor / Petravić, Damir / Lakusić, Darija Mahović / Hajnsek, Sanja / Lusić, Ivo / Bielen, Ivan / Basić, Silvio / Sporis, Davor / Soldo, Silva Butković / Antoncić, Igor / Anonymous4710747. ·Sestre milosrdnice University Hospital Center, University Department of Neurology, Referral Center for Neurovascular Diseases of the Ministry of Health of Republic Croatia, Zagreb, Croatia. vlasta.vukovic@uclmail.net ·Acta Clin Croat · Pubmed #23330402.

ABSTRACT: These guidelines have been developed to assist the physician in making appropriate choices in work-up and treatment of patients with headaches. The specific aim of the Evidence Based Guidelines for Treatment of Primary Headaches--2012 Update is to provide recommendations for establishing an accurate diagnosis and choose the most appropriate therapy in the group of patients with primary headaches, based on a comprehensive review and meta-analysis of scientific evidence with regard to treatment possibilities in Croatia. These data are based on our previous Evidence Based Guidelines for Treatment of Primary Headaches published in 2005 and other recommendations and guidelines for headache treatment.

13 Guideline Evidence-based guidelines for the chiropractic treatment of adults with headache. 2011

Bryans, Roland / Descarreaux, Martin / Duranleau, Mireille / Marcoux, Henri / Potter, Brock / Ruegg, Rick / Shaw, Lynn / Watkin, Robert / White, Eleanor. ·Guidelines Development Committee Chair and Chiropractor, Private Practice, Clarenville, Newfoundland and Labrador, Canada. rbryans@nfld.net ·J Manipulative Physiol Ther · Pubmed #21640251.

ABSTRACT: OBJECTIVE: The purpose of this manuscript is to provide evidence-informed practice recommendations for the chiropractic treatment of headache in adults. METHODS: Systematic literature searches of controlled clinical trials published through August 2009 relevant to chiropractic practice were conducted using the databases MEDLINE; EMBASE; Allied and Complementary Medicine; the Cumulative Index to Nursing and Allied Health Literature; Manual, Alternative, and Natural Therapy Index System; Alt HealthWatch; Index to Chiropractic Literature; and the Cochrane Library. The number, quality, and consistency of findings were considered to assign an overall strength of evidence (strong, moderate, limited, or conflicting) and to formulate practice recommendations. RESULTS: Twenty-one articles met inclusion criteria and were used to develop recommendations. Evidence did not exceed a moderate level. For migraine, spinal manipulation and multimodal multidisciplinary interventions including massage are recommended for management of patients with episodic or chronic migraine. For tension-type headache, spinal manipulation cannot be recommended for the management of episodic tension-type headache. A recommendation cannot be made for or against the use of spinal manipulation for patients with chronic tension-type headache. Low-load craniocervical mobilization may be beneficial for longer term management of patients with episodic or chronic tension-type headaches. For cervicogenic headache, spinal manipulation is recommended. Joint mobilization or deep neck flexor exercises may improve symptoms. There is no consistently additive benefit of combining joint mobilization and deep neck flexor exercises for patients with cervicogenic headache. Adverse events were not addressed in most clinical trials; and if they were, there were none or they were minor. CONCLUSIONS: Evidence suggests that chiropractic care, including spinal manipulation, improves migraine and cervicogenic headaches. The type, frequency, dosage, and duration of treatment(s) should be based on guideline recommendations, clinical experience, and findings. Evidence for the use of spinal manipulation as an isolated intervention for patients with tension-type headache remains equivocal.

14 Guideline Neurophysiological tests and neuroimaging procedures in non-acute headache (2nd edition). 2011

Sandrini, G / Friberg, L / Coppola, G / Jänig, W / Jensen, R / Kruit, M / Rossi, P / Russell, D / Sanchez del Rìo, M / Sand, T / Schoenen, J / Anonymous2400673. ·University Centre for Adaptive Disorders and Headache (UCADH), IRCCS C. Mondino Foundation, Pavia, Italy. giorgio.sandrini@mondino.it ·Eur J Neurol · Pubmed #20868464.

ABSTRACT: BACKGROUND AND PURPOSE: A large number of instrumental investigations are used in patients with non-acute headache in both research and clinical fields. Although the literature has shown that most of these tools contributed greatly to increasing understanding of the pathogenesis of primary headache, they are of little or no value in the clinical setting. METHODS: This paper provides an update of the 2004 EFNS guidelines and recommendations for the use of neurophysiological tools and neuroimaging procedures in non-acute headache (first edition). Even though the period since the publication of the first edition has seen an increase in the number of published papers dealing with this topic, the updated guidelines contain only minimal changes in the levels of evidence and grades of recommendation. RESULTS: (i) Interictal EEG is not routinely indicated in the diagnostic evaluation of patients with headache. Interictal EEG is, however, indicated if the clinical history suggests a possible diagnosis of epilepsy (differential diagnosis). Ictal EEG could be useful in certain patients suffering from hemiplegic or basilar migraine. (ii) Recording evoked potentials is not recommended for the diagnosis of headache disorders. (iii) There is no evidence warranting recommendation of reflex responses or autonomic tests for the routine clinical examination of patients with headache. (iv) Manual palpation of pericranial muscles, with standardized palpation pressure, can be recommended for subdividing patient groups but not for diagnosis. Pain threshold measurements and EMG are not recommended as clinical diagnostic tests. (v) In adult and pediatric patients with migraine, with no recent change in attack pattern, no history of seizures, and no other focal neurological symptoms or signs, the routine use of neuroimaging is not warranted. In patients with trigeminal autonomic cephalalgia, neuroimaging should be carefully considered and may necessitate additional scanning of intracranial/cervical vasculature and/or the sellar/orbital/(para)nasal region. In patients with atypical headache patterns, a history of seizures and/or focal neurological symptoms or signs, MRI may be indicated. (vi) If attacks can be fully accounted for by the standard headache classification (IHS), a PET or SPECT scan will normally be of no further diagnostic value. Nuclear medical examinations of the cerebral circulation and metabolism can be carried out in subgroups of patients with headache for the diagnosis and evaluation of complications, when patients experience unusually severe attacks or when the quality or severity of attacks has changed. (vii) Transcranial Doppler examination is not helpful in headache diagnosis. CONCLUSION: Although many of the examinations described in the present guidelines are of little or no value in the clinical setting, most of the tools, including thermal pain thresholds and transcranial magnetic stimulation, have considerable potential for differential diagnostic evaluation as well as for the further exploration of headache pathophysiology and the effects of pharmacological treatment.

15 Guideline Guidance for the management of headache in sport on behalf of The Royal College of General Practitioners and The British Association for the Study of Headache. 2011

Kernick, David P / Goadsby, Peter J / Anonymous170667 / Anonymous180667. ·St. Thomas Health Centre, Cowick Street, Exeter, UK. su1838@eclipse.co.uk ·Cephalalgia · Pubmed #20670994.

ABSTRACT: Headache is prevalent within the community and can have an impact on sport in both the amateur and elite player, either coincidentally or as a direct result of participation. Against a background of a limited evidence base, this paper suggests how headache can be classified within this context and offers guidance for treating both the amateur and elite athlete. The impact of headache in sport may be unrecognised and undertreated, and further research is needed in this area.

16 Guideline Ethical issues arising from commercial sponsorship and from relationships with the pharmaceutical industry--report and recommendations of the Ethics Subcommittee of the International Headache Society. 2008

Steiner, Timothy J. · ·Cephalalgia · Pubmed #18666973.

ABSTRACT: -- No abstract --

17 Editorial THINK of Ketamine for Headache. 2019

Goodnough, Robert. ·Department of Emergency Medicine, University of California San Francisco, San Francisco, California; California Poison Control System, San Francisco Division, San Francisco, California. ·J Emerg Med · Pubmed #30979402.

ABSTRACT: -- No abstract --

18 Editorial Persistent Headache Attributed to Traumatic Injury to the Head: Can We Do Better? 2019

Becker, Werner J. ·Department of Clinical Neurosciences,University of Calgary,Calgary,AB,Canada(WJB). ·Can J Neurol Sci · Pubmed #30688200.

ABSTRACT: -- No abstract --

19 Editorial When no cause can be found. 2018

Skjeldal, Ola H. · ·Tidsskr Nor Laegeforen · Pubmed #30180483.

ABSTRACT: -- No abstract --

20 Editorial Migraine disability complicated by medication overuse. 2018

Martelletti, P. ·Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy. ·Eur J Neurol · Pubmed #29938876.

ABSTRACT: -- No abstract --

21 Editorial Early management of medication-overuse headache - to remove or to add medication? 2018

Lundqvist, C. ·HØKH Health Services Research Unit and Department of Neurology, Akershus University Hospital and Institute of Clinical Medicine, University of Oslo, Lørenskog, Norway. ·Eur J Neurol · Pubmed #29682863.

ABSTRACT: -- No abstract --

22 Editorial Editorial for Pain: Nonmalignant Diseases in 2018. 2018

Dickenson, Anthony H / Bannister, Kirsty. ·Neuroscience, Physiology and Pharmacology, University College London. · Pharmacology, Wolfson CARD, Guy's Campus, King's College London, London, UK. ·Curr Opin Support Palliat Care · Pubmed #29608465.

ABSTRACT: -- No abstract --

23 Editorial Headaches in Children. 2018

Sivaswamy, Lalitha / Kamat, Deepak. · ·Pediatr Ann · Pubmed #29446793.

ABSTRACT: -- No abstract --

24 Editorial A Practical Look at Diagnosis and Management of Headaches, Anemia, and Our Role as Pediatric Providers. 2018

Hageman, Joseph R. · ·Pediatr Ann · Pubmed #29446791.

ABSTRACT: -- No abstract --

25 Editorial P-Hacking in Headache Research. 2018

Turner, Dana P. ·Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA. ·Headache · Pubmed #29411370.

ABSTRACT: -- No abstract --

Next